AURA | Aura Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.01 - 8.42
52 Week Range	6.63 - 12.38
Beta	1.23
Implied Volatility	353.69%
IV Rank	12.13%
Day's Volume	569,925
Average Volume	199,606
Shares Outstanding	49,951,466
Market Cap	409,602,021
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-29

Valuation
Profitability
Growth
Health
P/E Ratio	-4.74
Forward P/E Ratio	N/A
EPS	-1.73
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	88
Country	USA
Website	AURA

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

AURA's peers: AVTE, ADAG, ACRV, RZLT, ANTX, SEER, ORIC, ANEB, CGEM, CCCC, CRNX, ALXO, IMTX, BCAB, OPT

*Chart delayed

Analyzing fundamentals for AURA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see AURA Fundamentals page.

Watching at AURA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AURA Technicals page.